Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 June 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's share capital as of 31 May 2024. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the reporting period. The number of ordinary shares remained at 5,000,000,000 shares with a face value of $0.00001 per share and a total regulated/registered share capital of $50,000. In addition, the Company's stock options plan to remain at 436,000 during the month without any change in the number of new share options, and no new shares will be issued as a result of the exercise of share options. The report also confirms that all securities issued have been formally authorized by the Board of Directors and comply with relevant legal requirements.

Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 June 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's share capital as of 31 May 2024. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the reporting period. The number of ordinary shares remained at 5,000,000,000 shares with a face value of $0.00001 per share and a total regulated/registered share capital of $50,000. In addition, the Company's stock options plan to remain at 436,000 during the month without any change in the number of new share options, and no new shares will be issued as a result of the exercise of share options. The report also confirms that all securities issued have been formally authorized by the Board of Directors and comply with relevant legal requirements.